Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.05%
#3 Meteora Meteora +11.55%
#4 Bitway Bitway +10.13%
#5 Glidr Glidr +9.59%
#6 Unit Pump Unit Pump +8.98%
#7 Pump.fun Pump.fun +8.98%
#8 OPENLOOT OPENLOOT +8.59%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.72%
#10 eCash eCash +7.02%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rank in Stocks #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Share Price
$0.55
Last synced: 2025-02-11
Market Cap
$28.90M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Marinus Pharmaceuticals, Inc. (MRNS)

Category

Healthcare
Revenue for Marinus Pharmaceuticals, Inc. (MRNS)
Revenue in Sep 2024 TTM: $31.47M
According to Marinus Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $31.47M. In 2022 the company made a revenue of $25.48M an increase over the revenue in the year 2021 that was $15.35M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Marinus Pharmaceuticals, Inc. from 2012 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH